{"id":"dtacp-ipv-hib","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability"},{"rate":null,"effect":"Drowsiness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This pentavalent vaccine contains diphtheria and tetanus toxoids, acellular pertussis antigens, inactivated poliovirus antigens, and Haemophilus influenzae type b conjugate antigen. Upon administration, these antigens stimulate the immune system to produce antibodies and cellular immunity against these five pathogens, providing protection against the corresponding infectious diseases.","oneSentence":"DTacP-IPV/Hib is a combination vaccine that provides immunization against diphtheria, tetanus, acellular pertussis, poliomyelitis, and Haemophilus influenzae type b through inactivated antigens and toxoids.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:15.338Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children"}]},"trialDetails":[{"nctId":"NCT07112144","phase":"PHASE3","title":"Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial","status":"RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2025-06-13","conditions":"Prevent Whooping Cough, Prevent Diphtheria, Prevent Tetanus","enrollment":1650},{"nctId":"NCT06184542","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine","status":"RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2023-12-23","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":460},{"nctId":"NCT00654901","phase":"PHASE3","title":"Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":881},{"nctId":"NCT01491087","phase":"PHASE4","title":"Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-12","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":900},{"nctId":"NCT00303316","phase":"PHASE3","title":"Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":458},{"nctId":"NCT00453570","phase":"PHASE3","title":"Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-03","conditions":"Diphtheria, Tetanus, Haemophilus Influenzae Type b","enrollment":792},{"nctId":"NCT01214889","phase":"PHASE3","title":"Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-09","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":370},{"nctId":"NCT00259337","phase":"PHASE3","title":"Immunogenicity and Safety of Pentaxim™ in an Indian Population","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Diphtheria, Tetanus, Polio","enrollment":226}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DTacP-IPV/Hib","genericName":"DTacP-IPV/Hib","companyName":"Changchun BCHT Biotechnology Co.","companyId":"changchun-bcht-biotechnology-co","modality":"Biologic","firstApprovalDate":"","aiSummary":"DTacP-IPV/Hib is a combination vaccine that provides immunization against diphtheria, tetanus, acellular pertussis, poliomyelitis, and Haemophilus influenzae type b through inactivated antigens and toxoids. Used for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}